The Pharmalot View

The Pharmalot View Ed Silverman

STAT Plus: If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

The Pharmalot View Ed Silverman

STAT Plus: Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

The Pharmalot View Ed Silverman

STAT Plus: ‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

The Pharmalot View Ed Silverman

STAT Plus: Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

The Pharmalot View Ed Silverman

By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.

The Pharmalot View Ed Silverman

‘Where is Rudy?’: Inside Giuliani’s checkered track record as a pharma consultant

The Pharmalot View Ed Silverman

Oh, the irony! Trump may like to vilify drug makers, but now he needs them more than ever

The Pharmalot View Ed Silverman

FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’

The Pharmalot View Ed Silverman

STAT Plus: Operation Warp Speed doesn’t have the transparency it needs

The Pharmalot View Ed Silverman

STAT Plus: We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

The Pharmalot View Ed Silverman

STAT Plus: The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?

The Pharmalot View Ed Silverman

STAT Plus: Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

The Pharmalot View Ed Silverman

STAT Plus: Kapoor certainly deserves to go to jail, but so do some other pharma execs

The Pharmalot View Ed Silverman

STAT Plus: If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

The Pharmalot View Ed Silverman

STAT Plus: Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

The Pharmalot View Ed Silverman

STAT Plus: Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

The Pharmalot View Ed Silverman

STAT Plus: Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The Pharmalot View Ed Silverman

STAT Plus: The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

The Pharmalot View Ed Silverman

STAT Plus: The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

The Pharmalot View Ed Silverman

STAT Plus: One of the world’s largest drug makers is paying docs again — and patients are the worse off

The Pharmalot View Ed Silverman

STAT Plus: From zero to hero: J&J CEO praises Trump one year after chastising him

The Pharmalot View Ed Silverman

STAT Plus: When modest is actually excessive: AstraZeneca spins its price hikes

The Pharmalot View Ed Silverman

STAT Plus: He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

The Pharmalot View Ed Silverman

STAT Plus: Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

The Pharmalot View Ed Silverman

STAT Plus: Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines